



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 48/00, C12N 5/10, 15/09, 15/63</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/08713</b>  <b>(43) International Publication Date:</b> 25 February 1999 (25.02.99)						
<p><b>(21) International Application Number:</b> PCT/US98/16739</p> <p><b>(22) International Filing Date:</b> 13 August 1998 (13.08.98)</p> <p><b>(30) Priority Data:</b></p> <table border="0"> <tr> <td>60/055,520</td> <td>13 August 1997 (13.08.97)</td> <td>US</td> </tr> <tr> <td>60/075,113</td> <td>11 February 1998 (11.02.98)</td> <td>US</td> </tr> </table> <p><b>(71) Applicant (for all designated States except US):</b> THE UAB RESEARCH FOUNDATION [US/US]; Suite 1120G, 701 South 20th Street, Birmingham, AL 35294-0111 (US).</p> <p><b>(72) Inventors; and</b></p> <p><b>(75) Inventors/Applicants (for US only):</b> TANG, De-chu [-/US]; 1163 Riverchase Parkway, Birmingham, AL 35244 (US). MARKS, Donald, H. [US/US]; 12 Legion Court, Rockaway, NJ 07866 (US). CURIEL, David, T. [US/US]; 824 Lindwood Road, Birmingham, AL 35222 (US). SHI, Zhongkai [CN/US]; Apartment 2, 1611 94th Avenue South, Birmingham, AL 35205 (US).</p> <p><b>(74) Agents:</b> COGEN, Ellen, S. et al.; Gifford, Krass, Groh, Sprinkle, Patmore, Anderson &amp; Citkowski, P.C., Suite 400, 280 N. Old Woodward Avenue, Birmingham, MI 48009-5394 (US).</p>		60/055,520	13 August 1997 (13.08.97)	US	60/075,113	11 February 1998 (11.02.98)	US	<p><b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b>  <i>With international search report.</i></p>
60/055,520	13 August 1997 (13.08.97)	US						
60/075,113	11 February 1998 (11.02.98)	US						
<b>(54) Title:</b> VACCINATION BY TOPICAL APPLICATION OF GENETIC VECTORS								
<p><b>(57) Abstract</b></p> <p>The present invention provides a method of inducing an immune response in a non-invasive mode, comprising the step of: contacting skin of an individual in need of such treatment topically by applying to said skin an immunologically effective concentration of a genetic vector encoding a gene of interest. Also provided is a method of inducing an anti-tumor immune response in an animal in need of such treatment, comprising the step of: contacting skin of said animal topically by applying to said skin an immunologically effective concentration of a vector encoding a gene which encodes an antigen which induces an anti-tumor effect in said animal following administration. The genetic vector may include adenovirus recombinants, DNA/adenovirus complexes, DNA/liposome complexes, or any other vectors capable of expressing transgenes. Topical application of genetic vectors may preferably include a device as designed therein.</p>								

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**VACCINATION BY TOPICAL  
APPLICATION OF GENETIC VECTORS**

This application claims priority of United States Provisional Application No. 60/055,520, filed August 13, 1997 and United States Provisional Application  
5 No. 60/075,113, filed February 11, 1998.

**Background of the Invention**

**Field of the Invention**

The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to techniques  
10 of skin-targeted non-invasive gene delivery to elicit immune responses and uses thereof.

**Description of the Related Art**

Activation of the immune system of vertebrates is an important mechanism for protecting animals against pathogens and malignant tumors. The immune  
15 system consists of many interacting components including the humoral and cellular branches. Humoral immunity involves antibodies that directly bind to antigens. Antibody molecules as the effectors of humoral immunity are secreted by B lymphocytes. Cellular immunity involves specialized cytotoxic T lymphocytes (CTLs) which recognize and kill other cells which produce non-self  
20 antigens. CTLs respond to degraded peptide fragments that appear on the surface of the target cell bound to MHC (major histocompatibility complex) class I molecules. It is understood that proteins produced within the cell are continually degraded to peptides as part of cellular metabolism. These fragments are bound

to the MHC molecules and are transported to the cell surface. Thus the cellular immune system is constantly monitoring the spectra of proteins produced in all cells in the body and is poised to eliminate any cells producing non-self antigens.

Vaccination is the process of priming an animal for responding to an antigen. The antigen can be administered as a protein (classical) or as a gene which then expresses the antigen (genetic immunization). The process involves T and B lymphocytes, other types of lymphoid cells, as well as specialized antigen presenting cells (APCs) which can process the antigen and display it in a form which can activate the immune system. Current modes for the administration of genetic vaccines has focused on invasive procedures including needle injections, scarification, and gene gun-mediated penetration. Inoculation of vaccines in an invasive mode requires equipment and personnel with special medical training, and is usually associated with discomfort and potential hazards (bleeding, infection). There is now evidence that the inoculation of vaccines in an invasive mode may be unnecessary (Tang et al., 1997; Glenn et al., 1998). Since the skin interfaces directly with the external environment and is in constant contact with potential pathogens, the immune system must constantly keep a mobilized biological army along the skin border for warding off potential infections. As a consequence, the outer layer of skin is essentially an immunocompetent tissue. Immunologic components present in the skin for the elicitation of both humoral and cytotoxic cellular immune responses include epidermal Langerhans cells (which are MHC class II-positive antigen-presenting cells), keratinocytes, and both CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes. These components make the skin an ideal

site for administration of vaccine. The large accessible area of skin and its durability are other advantages for applying vaccines to this tissue. Expression of a small number of antigens in the outer layer of skin without physical penetration may thus elicit a potent immune response by alarming the immune surveillance  
5 mechanism.

The efficacy of a vaccine is measured by the extent of protection against a later challenge by a tumor or a pathogen. Effective vaccines are immunogens that can induce high titer and long-lasting immunity for targeted intervention against diseases after a minimum number of inoculations. For example, genetic  
10 immunization is an approach to elicit immune responses against specific proteins by expressing genes encoding the proteins in an animal's own cells. The substantial antigen amplification and immune stimulation resulting from prolonged antigen presentation *in vivo* can induce a solid immunity against the antigen. Genetic immunization simplifies the vaccination protocol to produce  
15 immune responses against particular proteins because the often difficult steps of protein purification and combination with adjuvant, both routinely required for vaccine development, are eliminated. Since genetic immunization does not require the isolation of proteins, it is especially valuable for proteins that may lose conformational epitopes when purified biochemically. Genetic vaccines may also  
20 be delivered in combination without eliciting interference or affecting efficacy (Tang et al., 1992; Barry et al., 1995), which may simplify the vaccination scheme against multiple antigens. It has been demonstrated, as presented in this application, that genetic vaccines can be inoculated in a novel way as skin-targeted

non-invasive vaccines. The combination of genetic vaccines with a non-invasive delivery mode may result in a new class of “democratic” vaccines that require no special skill and equipment for administration.

5 While topically-applied protein-based vaccines have been studied, their usefulness may be limited. Although topical application of protein-based vaccines in conjunction with cholera toxin may also immunize animals in the same non-invasive mode (Glenn et al., 1998) as skin-targeted non-invasive genetic vaccines have already been shown to do (Tang et al., 1997), the two classes of vaccines activate the immune system via different mechanisms. Further, the efficacy of  
10 genetic vaccines is in general superior to that of protein vaccines due to the *de novo* synthesis of antigens similar to natural infections (McDonnell and Askari, 1996). Although U.S. Pat. No. 3,837,340 describes a method for vaccinating animals by contacting skin with dried viruses, the viruses that they employ are not genetic vectors capable of expressing transgenes. In addition, the immunogen  
15 may be protein in the viral coat, instead of protein produced from expression of viral genes in animals’ own cells.

The prior art of vaccination usually requires equipment, e.g., syringe needles or a gene gun, and special skill for the administration of vaccines. There is a great need and desire in the art for the inoculation of vaccines by personnel  
20 without medical training and equipment. A large number of diseases could potentially be immunized against through the development of non-invasive vaccination onto the skin (NIVS) because the procedure is simple, effective, economical, painless, and potentially safe. As a consequence, NIVS may boost

vaccine coverages in developing countries where medical resources are in short supply, as well as in developed countries due to patient comfort. Infectious diseases caused by viruses, including AIDS and flu, by bacteria, including tetanus and TB, and by parasites, including malaria, and malignant tumors including a wide variety of cancer types may all be prevented or treated with skin-targeted non-invasive vaccines without requiring special equipment and medical personnel. The present invention satisfies this longstanding need and desire in the art.

### **Summary of the Invention**

Non-invasive vaccination onto the skin (NIVS) can improve vaccination schemes because skin is an immunocompetent tissue and this non-invasive procedure requires no specially trained personnel. Skin-targeted non-invasive gene delivery can achieve localized transgene expression in the skin and the elicitation of immune responses (Tang et al., 1997). These results indicate that NIVS is a novel and efficient method for the delivery of vaccines. The simple, effective, economical and painless immunization protocol of the present invention should make vaccination less dependent upon medical resources and, therefore, increase the annual utilization rate of vaccinations.

The present invention provides a method for immunizing animals comprising the step of skin-targeted non-invasive delivery of a preparation comprising genetic vectors, whereby the vector is taken up by epidermal cells and has an immunogenic effect on vertebrates. Also provided is a method for immunizing animals by a delivery device, comprising the steps of including

genetic vectors in the delivery device and contacting the naked skin of a vertebrate with a uniform dose of genetic material confined within the device, whereby the vector is taken up by epidermal cells for expressing a specific antigen in the immunocompetent skin tissue. The genetic vector may be adenovirus recombinants, DNA/adenovirus complexes, DNA/liposome complexes, or any  
5 other genetic vectors capable of expressing antigens in the skin of a vertebrate.

In one embodiment of the present invention, there is provided a method of inducing an immune response, comprising the step of: contacting skin of an individual or animal in need of such treatment by topically applying to said skin  
10 an immunologically effective concentration of a genetic vector encoding a gene of interest.

In another embodiment of the present invention, there is provided a method of inducing a protective immune response in an individual or animal in need of such treatment, comprising the step of: contacting the skin of said animal  
15 by topically applying to said skin an immunologically effective concentration of a vector encoding a gene which encodes an antigen which induces a protective immune effect in said individual or animal following administration.

In another embodiment, the invention presents a method for co-expressing transgenes in the same cell by contacting naked skin with DNA/adenovirus  
20 complexes. This protocol may allow the manipulation of the immune system by co-producing cytokines, costimulatory molecules, or other immune modulators with antigens within the same cellular environment.



The present invention also encompasses the use of a delivery device (bandages, adhesive dressings, or the like) for the delivery of skin-targeted non-invasive vaccines.

5 The present invention includes all genetic vectors for all of the uses contemplated in the methods described herein. Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

#### **Brief Description of the Drawings**

10 So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the  
15 specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

Figure 1 shows the transgene expression from adenovirus recombinants in the skin by topical application of the vectors;

20 Figures 2a and 2b show the characterization of potential target cells that can be transduced by topically-applied adenovirus recombinants;

Figures 3a and 3b show the detection of specific antibodies in the sera of mice immunized by adenovirus-mediated NIVS;

Figure 4 shows the percent survival of control versus immunized mice that were challenged by a lethal dose of tumor cells;

5           Figure 5 shows the characterization of tumor-infiltrating T lymphocytes;

Figure 6 shows the characterization of tumor-infiltrating CTLs;

Figure 7 shows the western blot analysis of antibodies to the human CEA protein in mice immunized by topical application of vaccine bandages;

10           Figure 8a shows the detection of specific antibodies in the serum of a mouse immunized by DNA/adenovirus-mediated NIVS;

Figure 8b shows the detection of specific antibodies in the serum of a mouse immunized by DNA/liposome-mediated NIVS;

Figure 9 shows the co-expression of DNA-encoded and adenovirus-encoded transgenes in target cells;

15           Figure 10 shows relative transgene expression from topically-applied adenovirus recombinants, DNA/adenovirus complexes, and DNA/liposome complexes;

Figure 11 shows a device for the administration of skin-targeted non-invasive vaccines.

20                           **Detailed Description of the Invention**

The present invention is directed to a method of inducing an immune response, comprising the step of contacting the outer layer of skin of an individual

or animal in need of such treatment with an immunologically effective concentration of a genetic vector containing a gene of interest without physical invasiveness for a period of time suitable to elicit an immune response thereto. Representative examples of antigens which can be used to produce an immune response using the methods of the present invention include the human carcinoembryonic antigen, the HIV gp120, the tetanus toxin C-fragment, and the influenza HA and NP, etc. Most preferably, the immune response produces a protective effect against neoplasms or infectious pathogens.

The practice of the present invention requires delivering genetic vectors operatively coding for a polypeptide into the outer layer of skin of a vertebrate by a non-invasive procedure for immunizing the animal. These genetic vectors can be administered to the vertebrate by direct transfer of the genetic material to the skin without utilizing any devices, or by contacting naked skin utilizing a bandage or a bandage-like device. In preferred applications, the genetic vector is in aqueous solution. Vectors reconstituted from lyophilized powder are also acceptable. The vector may encode a complete gene, a fragment of a gene or several genes, gene fragments fused with immune modulatory sequences such as ubiquitin or CpG-rich synthetic DNA, together with transcription/translation signals necessary for expression.

In another embodiment of the present invention, the vector further contains a gene selected from the group consisting of co-stimulatory genes and cytokine genes. In this method the gene is selected from the group consisting of a GM-CSF

gene, a B7-1 gene, a B7-2 gene, an interleukin-2 gene, an interleukin-12 gene and interferon genes.

In the embodiments of the invention that require use of adenovirus recombinants, it may include E1-defective, E3-defective, and/or E4-defective  
5 adenovirus vectors, or the “gutless” adenovirus vector in which all viral genes are deleted. The E1 mutation raises the safety margin of the vector because E1-defective adenovirus mutants are replication incompetent in non-permissive cells. The E3 mutation enhances the immunogenicity of the antigen by disrupting the mechanism whereby adenovirus down-regulates MHC class I molecules. The E4  
10 mutation reduces the immunogenicity of the adenovirus vector by suppressing the late gene expression, thus may allow repeated re-vaccination utilizing the same vector. The “gutless” adenovirus vector is the latest model in the adenovirus vector family. Its replication requires a helper virus and a special human 293 cell line expressing both E1a and Cre, a condition that does not exist in natural  
15 environment; the vector is deprived of all viral genes, thus the vector as a vaccine carrier is non-immunogenic and may be inoculated for multiple times for re-vaccination. The “gutless” adenovirus vector also contains 36 kb space for accommodating transgenes, thus allowing co-delivery of a large number of antigen genes into cells. Specific sequence motifs such as the RGD motif may be inserted  
20 into the H-I loop of an adenovirus vector to enhance its infectivity. An adenovirus recombinant is constructed by cloning specific transgenes or fragments of transgenes into any of the adenovirus vectors such as those described above. The

adenovirus recombinant is used to transduce epidermal cells of a vertebrate in a non-invasive mode for use as an immunizing agent.

In the embodiments of the invention that require use of DNA/adenovirus complexes, it requires plasmid DNA complexed with adenovirus vectors utilizing  
5 either PEI (polyethylenimine) or polylysine. The adenovirus vector within the complex may be either "live" or "killed" by UV irradiation. The UV-inactivated adenovirus vector as a receptor-binding ligand and an endosomolysis agent for facilitating DNA-mediated transfection (Cotten et al., 1992) may raise the safety margin of the vaccine carrier. The DNA/adenovirus complex is used to transfect  
10 epidermal cells of a vertebrate in a non-invasive mode for use as an immunizing agent.

In the embodiments of the invention that require use of DNA/liposome complexes, it requires materials for forming liposomes, and requires that DNA/liposome complexes be made from these materials. The DNA/liposome  
15 complex is used to transfect epidermal cells of a vertebrate in a non-invasive mode for use as an immunizing agent.

Genetic vectors provided by the invention can also code for immune modulatory molecules which can act as an adjuvant to provoke a humoral and/or cellular immune response. Such molecules include cytokines, co-stimulatory  
20 molecules, or any molecules that may change the course of an immune response. One can conceive of ways in which this technology can be modified to enhance still further the immunogenicity of antigens.

The genetic vector used for NIVS can take any number of forms, and the present invention is not limited to any particular genetic material coding for any particular polypeptide. All forms of genetic vectors including viral vectors, bacterial vectors, protozoan vectors, and DNA vectors, when used as skin-targeted non-invasive vaccine carriers, are within the methods contemplated by the invention.

The genes can be delivered by various methods including device-free topical application or coating the genes on the surface of the skin of an animal by a device such as a pad or bandage; e.g., an adhesive bandage. Referring to Figure 11, a device for non-invasive vaccination is shown. This vaccine delivery device includes a non-allergenic, skin adhesive patch having a bleb disposed therein. In one embodiment, the patch is further comprised of plastic, approximately 1 cm in diameter. The vaccine can be disposed within the bleb. In another embodiment, the bleb contains approximately 1 mL of vaccine (as liquid, lyophilized powder with reconstituting fluid, and variants thereof). In a preferred embodiment, the surface of the bleb in contact with the skin is intentionally weaker than the opposite surface, such that when pressure is applied to the opposite surface, the lower surface breaks and releases the vaccine contents of the bleb onto the skin. The plastic patch traps the vaccine against the skin surface.

Dosage forms for the topical administration of the genetic vector and gene of interest of this invention can include liquids, ointments, powders, and sprays. The active component can be admixed under sterile conditions with a

physiologically acceptable carrier and any preservatives, buffers, propellants, or absorption enhancers as may be required.

In terms of the terminology used herein, an immunologically effective amount is an amount or concentration of the genetic vector encoding the gene of interest, that, when administered to an animal, produces an immune response to the gene product of interest.

Various antigens may be delivered topically at different concentrations. Generally, useful amounts for adenovirus vectors are at least approximately 100 pfu and for plasmid DNA at least approximately 1 ng of DNA.

The methods of the invention can be appropriately applied to prevent diseases as prophylactic vaccination or treat diseases as therapeutic vaccination.

The vaccines of the present invention can be administered to an animal either alone or as part of an immunological composition.

Beyond the human vaccines described, the method of the invention can be used to immunize animal stocks. The term animal means all animals including humans. Examples of animals include humans, cows, dogs, cats, goats, sheep, and pigs, etc. Since the immune systems of all vertebrates operate similarly, the applications described can be implemented in all vertebrate systems.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

## **Protocols**

### **Mice and cell cultures**

Inbred mice were maintained at the University of Alabama at Birmingham. Cells were cultured in RPMI 1640 or DMEM media containing 2% fetal bovine serum and 6% calf serum.

### **Topical application of genetic vectors**

Mice were anesthetized and hair and cornified epithelium covering a restricted area of abdominal or neck skin were removed by a depilatory (e.g., NAIR). Genetic vectors were pipetted onto the preshaved and NAIR-treated skin and kept in contact with naked skin for varying amounts of time (e.g., 1 hour to 18 hours). Vectors may be pipetted directly onto naked skin, or into a cylinder that is glued onto the skin.

### **Preparation of adenovirus vectors**

High titer adenovirus stocks were prepared from human 293 cells infected with specific adenovirus recombinants. Lysates were subjected to ultracentrifugation through a cesium chloride gradient. Viral bands were extracted and dialyzed against 10 mM Tris (pH 7.5)/135 mM NaCl/5 mM KCl/1 mM MgCl<sub>2</sub>. Purified viruses were filter sterilized with glycerol added to 10%, and stored in aliquots at -80°C. Titer for adenovirus stocks was determined by plaque assay.

### **Luciferase assay**

The amount of luciferase in the skin was determined as previously described (Tang, 1994). Briefly, a piece of excised skin was homogenized with



a Kontes glass tissue grinder in lysis buffer. After removing tissue debris by centrifugation, luciferase activity in the skin extract was determined with a luminometer by measurement of integrated light emission in the presence of excess ATP and luciferin.

5      $\beta$ -Galactosidase assay

A piece of excised skin was quickly frozen in Tissue-Tek O.C.T. compound (Miles Laboratories Inc.) in liquid nitrogen and stored at -80°C until use. The frozen tissue was cross sectioned at 4  $\mu$ m, fixed in 4% paraformaldehyde, and stained for  $\beta$ -galactosidase activity by incubation in X-gal staining solution as previously described (Tang et al., 1994). Sections were  
10     counterstained with haematoxylin and eosin.

Preparation of DNA/adenovirus complexes

DNA/adenovirus complexes were prepared by mixing 100  $\mu$ g plasmid DNA with  $1 \times 10^{11}$  particles of adenovirus in the presence of the condensing agent  
15     polylysine for each application. The titer of adenovirus was determined by absorbance.

Preparation of DNA/liposome complexes

DNA/liposome complexes were prepared by mixing 100  $\mu$ g plasmid DNA with 100  $\mu$ g DOTAP/DOPE (1:1; Avanti) for each application. Plasmids were  
20     prepared using Qiagen Plasmid Maxi Kits.

Western blot analysis

Sera from tail bleeds were diluted 1:250 to 1:500 and reacted with purified proteins that had been separated in a SDS-polyacrylamide gel and transferred to

an Immobilon-P membrane (Millipore). Reaction was visualized using the ECL kit (Amersham).

### **EXAMPLE 1**

The present invention demonstrates that antigen genes can be delivered  
5 into the skin of mice in a simplified manner by skin-targeted non-invasive delivery  
of a genetic vector without using sophisticated equipment. Figure 1 shows that  
substantial amounts of luciferase enzyme was produced after delivery of limited  
amounts of AdCMV-luc (an adenovirus vector encoding the firefly luciferase)  
(Tang et al., 1994) onto the skin. Ad, adenovirus; pfu, plaque-forming units; LU,  
10 light units. Results are the mean  $\log[\text{LU per cm}^2 \text{ skin}] \pm \text{SE}$  ( $n$  is shown on top of  
each column). Mice mock-applied or coated with an adenovirus vector that did  
not encode luciferase produced no detectable luciferase activity in the skin. The  
level of transgene expression from the adenovirus vector in the skin did not appear  
to correlate with the titer of the virus. It is possible that only a small number of  
15 cells can be transduced by the virus in a restricted subset of skin, and  $10^8$  plaque-  
forming units (pfu) of adenovirus recombinants may have saturated the target  
cells. This variability could also be due, in part, to variations of individual mice.  
In addition, some of the variability probably arose from the procedure for  
removing cornified epithelium which had not been standardized (Johnston and  
20 Tang, 1994). The amount of antigen produced may potentially be amplified by  
applying more vectors onto a larger area.

## **EXAMPLE 2**

The principal target cells for non-invasive vaccination onto the skin appeared to be hair matrix cells within hair follicles (Figure 2a) and keratinocytes within the outermost layer of epidermis (Figure 2b) as shown by staining frozen  
5 sections with X-gal substrates after skin-targeted non-invasive delivery of an adenovirus vector encoding the *E. coli*  $\beta$ -galactosidase gene (AdCMV- $\beta$ gal) (Tang et al., 1994). No physical abrasions were found in the skin tissue subjected to the treatment, and there was no inflammation induced. The skin tissue subjected to non-invasive gene delivery was excised from animals 1 day after pipetting  $10^8$  pfu  
10 of AdCMV- $\beta$ gal onto the skin, cross sectioned, fixed, and stained with X-gal substrates as described (Tang et al., 1994). Figure 2a shows the adenovirus-transduced hair matrix cells within a hair follicle, x150. Figure 2b shows the adenovirus-transduced keratinocytes within the outermost layer of epidermis, x150. No blue cells were found in control animals that were either mock-applied  
15 or coated with AdCMV-luc.

## **EXAMPLE 3**

### **Elicitation of humoral immune responses by adenovirus-mediated NIVS**

NIVS is a novel method for vaccinating animals. To demonstrate that the procedure can elicit a specific immune response against the antigen encoded by the  
20 vector, AdCMV-hcea [an adenovirus vector encoding the human carcinoembryonic antigen (CEA)] was pipetted onto the skin of the C57BL/6 strain mice. Serum from a vaccinated mouse a month after skin-targeted non-invasive delivery of  $10^8$  pfu AdCMV-hcea was diluted 1:500 and reacted with

purified human CEA protein (provided by T. Strong) and adenoviral proteins that had been separated in a 5% SDS-polyacrylamide gel, and transferred to Immobilon-P membranes (Millipore). Referring to Figure 3a, lane 1, 0.5  $\mu$ g of human CEA; lane 2, 0.5  $\mu$ g of BSA; lane 3,  $10^7$  pfu of adenovirus. Figure 3a shows that the test sera from a vaccinated animal reacted in western blots with purified human CEA protein, but not with bovine serum albumin (BSA), which supports the conclusion that specific antibodies have been produced against exogenous proteins encoded by adenovirus vectors as a result of skin-targeted non-invasive gene delivery.

To test whether this technique might be generally applicable, AdCMV-hgmcsf [an adenovirus vector encoding the human granulocyte macrophage colony stimulating factor (hGM-CSF)] was applied onto the skin. To detect antibodies against the human GM-CSF protein, the animal was vaccinated by skin-targeted non-invasive delivery of  $10^8$  pfu of AdCMV-hgmcsf. Purified human GM-CSF protein (CalBiochem) separated in a 15% SDS-polyacrylamide gel was transferred to membranes and allowed to react with diluted serum. Other treatments were carried out as described in Figure 3a. Referring to Figure 3b, lane 1, 0.25  $\mu$ g of human GM-CSF; lane 2, 0.25  $\mu$ g of BSA; lane 3,  $10^7$  pfu of adenovirus. The replication-defective human adenovirus serotype 5 derived AdCMV-hcea and AdCMV-hgmcsf were produced in human 293 cells. A cassette containing the human CEA gene or the human GM-CSF gene, driven by the cytomegalovirus (CMV) early enhancer-promoter element was inserted in place of the E1a deletion.

Since the sequences in the E1a region were deleted, the ability of these viruses to replicate autonomously in nonpermissive cells was impaired.

Results (Tang et al., 1997) show that 96% (23/24) of the C57BL/6 strain mice produced antibodies against the human CEA protein a month after skin-targeted non-invasive delivery of AdCMV-hcea, and 43% (6/14) of the same strain mice produced antibodies against the human GM-CSF protein after skin-targeted non-invasive delivery of AdCMV-hgmcsf. Both pre-immune sera collected before NIVS and sera from naive animals failed to react with the human CEA and GM-CSF proteins. The possibility of oral vaccination by ingesting vectors through grooming was eliminated by (1) rinsing vectors away from the skin before animals recovered from anesthesia, (2) pipetting vectors onto unshaved skin, and (3) mixing naive and vaccinated animals in the same cage. No cross-vaccination between naive and vaccinated mice was ever observed, and shaving appeared as an essential component for NIVS presumably due to the mechanical removal of cornified epithelium along the shaving path. Thus, adenovirus-mediated NIVS is capable of eliciting a humoral immune response against an antigen encoded by the vector.

#### **EXAMPLE 4**

To demonstrate that the techniques of the present invention can elicit a protective antitumor immune response, syngeneic tumor cells that express the human carcinoembryonic antigen (CEA) gene (MC38-CEA-2) (Conry et al., 1995) were inoculated into naive C57BL/6 strain mice and the same strain mice that had been vaccinated by topical application of an adenovirus vector encoding the

human CEA gene (AdCMV-hcea). Animals subjected to tumor challenges were observed for survival (Figure 4). In the control group, 90% (9/10) of the animals developed palpable tumor nodules and died within 30 days after tumor cell implantation. In the vaccinated group, only 10% (1/10) of the animals died, and 5 70% (7/10) of them remained totally tumor-free. Mice were euthanized when the tumor exceeded 1 cm in diameter. The interval between tumor cell injection and euthanization is used as the individual survival time. Referring to Figure 4, control mice (no vaccines were administered) and animals immunized by NIVS ( $10^8$  pfu of AdCMV-hcea were topically applied a month before) were subjected 10 to tumor challenges. Numbers in parentheses represent the number of animals for each treatment. Results show that non-invasive delivery of genetic vaccines onto the skin may be able to elicit protective immune responses against tumor cells expressing a specific antigen.

#### **EXAMPLE 5**

##### **Construction of recombinant adenovirus vectors encoding cytokine and co-stimulatory genes**

Adenovirus vectors encoding co-stimulatory and cytokine genes were constructed for the co-delivery of these immune-modulatory genes with antigen genes into skin cells in an attempt to direct the immune profile in vaccinated 20 animals. The adenovirus vector AdCMV-mB7.1 encoding the murine B7-1 gene and the adenovirus vector AdCMV-mgmcsf encoding the murine GM-CSF gene were constructed by homologous recombination between two transfected plasmids in human 293 cells following a standard procedure for generating new adenovirus

vectors (Gomez-Foix et al., 1992). All transgenes in these vectors were transcriptionally driven by the CMV early enhancer-promoter element. AdCMV-mB7.1 was characterized by staining transduced human lung carcinoma SCC-5 cells with the anti-CD80 antibody (PharMingen), followed by flow cytometric analysis. AdCMV-mgmcsf was characterized by measuring murine GM-CSF secreted from transduced SCC-5 cells with an ELISA kit (Amersham).

#### **EXAMPLE 6**

##### Detection of antitumor immunity by *in vivo* cytotoxicity assay

An *in vivo* cytotoxicity assay was developed in which target cells were implanted as monolayers onto the muscle tissue of mice (Tang et al., 1996). Implantation of target cells as monolayers allowed for an efficient retrieval of target cells for assessing their fates after a few days of *in vivo* growth. This assay was particularly useful for detecting weak immune responses that are not potent enough for eradicating target cells. Immune responses can be characterized by histological analysis of the implantation bed. Without an immune response, target cells would grow. With a potent immune response, target cells would be eradicated in the presence of a large number of immune effector cells at the implantation bed, probably by virtue of migration to and *in situ* sensitization around growing target cells. With a weak immune response, growing target cells would intermingle with infiltrating immune effector cells at the implantation bed. Implanting  $5 \times 10^5$  RM1-luc cells [RM1 prostate tumor cells expressing the luciferase gene] as a monolayer into naive C57BL/6 mice resulted in a tumor layer due to proliferation of RM1-luc cells *in vivo*, with no evidence of immune

intervention. In contrast to control animals, RM1-luc cells were intermingled with a large number of immune effector cells at the implantation bed in animals vaccinated by skin-targeted non-invasive delivery of AdCMV-luc.

#### **EXAMPLE 7**

##### **5 Characterization of immune effector cells recruited by tumor cells**

The *in vivo* cytotoxicity assay was able to concentrate a large number of immune effector cells at the implantation bed by implanting a small number of target cells as a monolayer onto muscle. Characterization of specific immune effector cells at the implantation bed may provide evidence as to whether a cell-

10 mediated immune response has been elicited for killing target cells. For characterizing T cells that were recruited by luciferase-expressing tumor cells in animals vaccinated by skin-targeted non-invasive delivery of AdCMV-luc, tissue sections of the implantation bed were stained with an anti-CD3 monoclonal antibody (mAb). RM1-luc cells were produced by lipofecting pHBA-luc DNA

15 into RM1 prostate tumor cells (provided by T. Thompson at the Baylor College of Medicine), followed by selection in medium containing G418. Clones expressing luciferase were characterized by luciferase assay. Five  $\times 10^5$  RM1-luc cells were implanted as a monolayer into a mouse that had been vaccinated by skin-targeted non-invasive delivery of  $10^8$  pfu AdCMV-luc. Five days after

20 implantation, the implantation bed was frozen in O.C.T. and sections were cut at 4  $\mu\text{m}$ , dried in 100% acetone, and stained with an anti-CD3 mAb (clone F500A2, provided by P. Bucy at UAB), via the ABC immunoperoxidase procedure with diaminobenzidine as the chromogen.



As shown in Figure 5, a large number of T cells infiltrated into the implantation bed after 5 days of *in vivo* growth of RM1-luc cells in a mouse vaccinated by skin-targeted non-invasive delivery of AdCMV-luc (x150) while only a few T cells were found in naive animals. It appeared that the same number of RM1-luc target cells could recruit more T lymphocytes to the implantation bed in vaccinated animals than in naive animals.

For characterizing CTLs that were recruited by target cells, frozen sections of the implantation bed were subjected to *in situ* hybridization using an antisense granzyme A RNA molecule as the probe. Five X 10<sup>5</sup> RM1-luc cells were implanted as a monolayer into either a naive C57BL/6 mouse or a mouse that had been vaccinated by skin-targeted non-invasive delivery of 10<sup>8</sup> pfu AdCMV-luc. Five days after implantation, the implantation bed was frozen in O.C.T. and sections were cut at 4 µm. Frozen sections were fixed in 3% paraformaldehyde, incubated in 0.2 M HCl for inhibiting endogenous alkaline phosphatase activity, and hybridized with a heat-denatured antisense granzyme A RNA probe. Probes for *in situ* hybridization were single-stranded RNA molecules produced by transcription from a plasmid containing bacteriophage promoters. During the transcription, digoxigenin-UTP was directly incorporated into the sequence. Sense sequence probes were used as negative controls. After hybridizing with probes, sections were washed and incubated with alkaline phosphatase-conjugated anti-digoxigenin antibody, followed by incubation in the NBT/BCIP enzyme substrate solution.

CTLs that express granzyme A are activated CTLs and have been used as predictive markers for tissue rejection during transplantation. Granzyme-positive CTLs were found within the RM1-luc implantation bed only in animals that had been vaccinated by skin-targeted non-invasive delivery of AdCMV-luc (Figure 6).  
5 Their presence at the bed suggests that a cell-mediated immune response against tumor cells expressing a specific antigen may have been induced by NIVS.

### **EXAMPLE 8**

#### **Topical application of genetic vaccines by adhesive bandages**

It was demonstrated, for the first time, that bandages could be used for the  
10 administration of vaccines. This development may allow personnel without medical training to deliver a uniform dose of non-invasive vaccines onto the skin. To transduce skin by bandage, 50 µl of the AdCMV-luc vector described in Example 7 was pipetted into the pad of an adhesive bandage (Johnson & Johnson). The vector-containing bandage was subsequently adhered to pre-shaved skin of a  
15 mouse. The vector was kept in contact with naked skin for 18 hours. To detect transgene expression from genetic vectors delivered by a bandage, the skin was assayed for luciferase (Table 1). While the results show substantial variation, transgene expression in the skin was achievable using adhesive bandages.

To demonstrate that animals could be vaccinated with non-invasive  
20 adhesive bandages, sera from tail bleeds were assayed for anti-CEA antibodies two months after adhering bandages containing AdCMV-hcea onto the skin of mice. As shown in Figure 7, anti-CEA antibodies were detected in 100% (10/10) of mice that received non-invasive vaccines through adhesive bandages.

**EXAMPLE 9****DNA/adenovirus-mediated NIVS**

Adenovirus-based vectors can be made more versatile by binding plasmid DNA to the exterior of an adenovirus. The resulting vector system mediates high-efficiency gene delivery to a wide variety of target cells. This approach allows greatly enhanced flexibility in terms of the size and design of foreign genes. DNA/adenovirus complexes may thus be able to deliver antigen genes into the skin via the same adenovirus receptor-mediated endocytosis pathway with more flexibility.

To demonstrate the feasibility of DNA/adenovirus-mediated NIVS, plasmid DNA encoding the human growth hormone (pCMV-GH) (Tang et al., 1992) was allowed to complex with an E4-defective adenovirus. Mice (strain C57BL/6) were vaccinated by contacting DNA/adenovirus complexes with naked skin for one day. Immunized animals were subsequently monitored for the production of antibodies against the human growth hormone protein (hGH) by assaying sera from tail-bleeds. As shown in Figure 8a, lane 1, hGH (0.5 µg); lane 2, BSA (0.5 µg), the test sera reacted in western blots with purified hGH, but not with irrelevant proteins. Of ten mice vaccinated by DNA/adenovirus complexes, eight (80%) produced antibodies against hGH within three months, indicating that specific antibodies could be produced against exogenous proteins encoded by plasmid DNA that is complexed with adenovirus and administered in a non-invasive mode. Pre-immune sera collected before treatment, sera from untreated animals, and sera from animals vaccinated with irrelevant vectors all failed to react

with hGH. Thus, DNA/adenovirus complexes, like adenovirus recombinants, appear as a legitimate vector system for NIVS.

#### **EXAMPLE 10**

##### **DNA/liposome-mediated NIVS**

5 In addition to developing genetic vectors involving adenovirus as carriers for non-invasive vaccines, it has also been demonstrated that mice could be vaccinated by topical application of DNA/liposome complexes without viral elements. It is apparent that many different vectors can be applied in a creative way for the administration of skin-targeted non-invasive vaccines. As shown in  
10 Figure 8b, lane 1, hGH (0.5  $\mu$ g); lane 2, BSA (0.5  $\mu$ g), the test serum from a mouse immunized by topical application of DNA/liposome complexes encoding hGH reacted with hGH but not with BSA. Of 10 mice vaccinated by DNA/liposome complexes, the test sera reacted with purified hGH in 9 (90%) treated animals within 5 months. Thus, the DNA/liposome complex, like the  
15 adenovirus and the DNA/adenovirus complex, appears as another legitimate vector system for NIVS.

#### **EXAMPLE 11**

##### **Co-expression of DNA-encoded and adenovirus-encoded transgenes**

20 Strategies of augmenting the immune system's response can potentially improve the clinical outcomes of vaccines. Local production of immune-modulatory molecules involved in the activation and expansion of lymphocyte populations may significantly improve the vaccination effects. Adenovirus vectors encoding the murine B7-1 and GM-CSF genes have been made. Topical

application of DNA/adenovirus complexes may thus be able to co-express DNA-encoded antigens or immune modulatory molecules with adenovirus-encoded antigens or immune modulatory molecules in individual skin cells for enhancing the immune response against the antigen.

5           Figure 9 shows that the expression of transgenes from plasmid DNA in target cells is dependent upon the presence of adenovirus, thus allowing plasmid-encoded and adenovirus-encoded transgenes to be co-expressed in the same cell. pVR-1216 plasmid DNA (provided by Vical), AdCMV- $\beta$ gal particles and polylysine were mixed at specific ratios as shown in the figure. The complex was  
10           applied to  $2 \times 10^5$  SCC-5 cells in a well and incubated for 2 hours. The complex was then removed and cells were harvested for luciferase and  $\beta$ -galactosidase assays the next day. Open column: luciferase activity; solid column:  $\beta$ -galactosidase activity. Results show that DNA-encoded transgenes are not  
15           expressed in target cells in the absence of adenovirus, whereas adenovirus-encoded transgenes can be expressed in the presence of DNA. It is also possible that DNA may be condensed onto the surface of other viruses for targeting different cell types. Accordingly, this protocol provides a simple but versatile gene delivery system which allows the expression of transgenes from both a virus recombinant and an externally-bound plasmid, simultaneously.

**EXAMPLE 12****Relative transgene expression in the skin from different genetic vectors by topical application**

It has been shown that adenovirus recombinants, DNA/adenovirus  
5 complexes, DNA/liposome complexes, and perhaps many other genetic vectors  
can all be applied as carriers for non-invasive vaccines. It is conceivable that the  
higher the efficiency for transgene expression, the more powerful the carrier will  
be. To define the relative efficiencies for the vectors utilized, adenovirus  
recombinants, DNA/adenovirus complexes, or DNA/liposome complexes were  
10 allowed to contact mouse skin by topical application for 18 hr. The treated skin  
was subsequently removed from the animal and assayed for luciferase activity with  
a luminometer by measurement of integrated light emission for 2 min using the  
Promega's luciferase assay system, and background was subtracted from the  
readings. As shown in Figure 10, adenovirus recombinants were found to be the  
15 most efficient vector system for skin-targeted non-invasive gene delivery. Mice  
mock-treated produced no detectable luciferase activity in the skin. LU, light  
units; Ad, AdCMV-luc; DNA/Ad, pVR-1216 DNA complexed with Ad dl1014;  
DNA/liposome, pVR-1216 DNA complexed with DOTAP/DOPE. Results are the  
mean log[LU per cm<sup>2</sup> skin]  $\pm$  SE (*n* is shown on top of each column). Although  
20 the efficiency of DNA/adenovirus complex is lower than that of adenovirus  
recombinant, it is significantly higher than that of DNA/liposome complex. In  
addition, adenovirus may be inactivated by UV irradiation before complexing with  
DNA to prevent viable viral particles from disseminating. Thus, DNA/adenovirus

complexes may appear as the most promising carrier system for the delivery of non-invasive vaccines when efficiency and safety factors are both considered in formulating a new generation of vaccines.

Any patents or publications mentioned in this specification are indicative  
5 of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will readily appreciate that the present invention is  
10 well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and  
15 other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

## REFERENCES

The following references were cited herein:

- Barry, M.A. et al. Protection against mycoplasma infection using expression-library immunization. *Nature* 377, 632-635 (1995).
- 5 Conry, R.M. et al. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. *Cancer Gene Ther.* 2, 33-38 (1995).
- Cotten, M. et al. High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. *Proc. Natl. Acad. Sci*  
10 *USA* 89, 6094-6098 (1992).
- Glenn, G.M. et al. Skin immunization made possible by cholera toxin. *Nature* 391, 851 (1998).
- Gomez-Foix et al. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen  
15 metabolism. *J.Biol. Chem.*, 267, 25129-25134 (1992).
- Johnston, S. A. & Tang, D.-c. Gene gun transfection of animal cells and genetic immunization. *Meth. Cell Biol.* 43, 353-365 (1994).
- McDonnell, W.M. & Askari, F.K. DNA vaccines. *New Engl. J. Med.* 334, 42-45 (1996).
- 20 Tang, D.-c. et al. Genetic immunization is a simple method for eliciting an immune response. *Nature* 356, 152-154 (1992).
- Tang, D.-c. et al. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. *Cancer Gene Ther.* 1, 15-20 (1994).
- Tang, D.-c. et al. In vivo cytotoxicity assay for assessing immunity. *J.*  
25 *Immunol. Methods* 189, 173-182 (1996).
- Tang, D.-c. et al. Vaccination onto bare skin. *Nature* 388, 729-730 (1997).



TABLE 1

Incubation time (hours)	LU per cm <sup>2</sup> skin
1	0
1	2,100
2	0
2	0
2	6,200
2	7,300
2	13,000
2	48,000
2	1,800
2	13,000
18	830
18	2,400
18	260
18	630
18	1,300,000
18	24,000
18	2,700
18	280

What is claimed is:

1           1.     A method of non-invasively inducing an immune response,  
2     comprising the step of: contacting skin of an animal in need of such treatment  
3     topically by applying to the skin an immunologically effective amount of a genetic  
4     vector encoding a transgene of interest.

1           2.     The method of claim 1, wherein the genetic vector comprises  
2     genetic vectors capable of expressing a transgene.

1           3.     The method of claim 2, wherein the genetic vector is selected from  
2     the group consisting of viral vector and plasmid DNA.

1           4.     The method of claim 2, wherein the genetic vector is an adenovirus.

1           5.     The method of claim 1, wherein the transgene encodes an antigen  
2     or fragment thereof.

1           6.     The method of claim 5, wherein the antigen or fragment thereof  
2     can be used to produce an immune response against a pathogen or neoplasm.

1           7.     The method of claim 5, wherein the antigen is selected from the  
2     group consisting essentially of the human carcinoembryonic antigen, the HIV

3 gp120 antigen, the tetanus toxin C-fragment and the influenza NP and HA  
4 antigens.

1 8. The method of claim 1, wherein the immunologically effective  
2 amount of the genetic vector is at least approximately 100 plaque forming units  
3 (pfu) for an adenovirus vector and at least 1 ng of DNA for plasmid.

1 9. The method of claim 2, wherein the vector encodes an immune  
2 modulatory gene.

1 10. The method of claim 9, wherein the vector further encodes a co-  
2 stimulatory gene and a cytokine gene.

1 11. The method of claim 9, wherein the immune modulatory gene is  
2 selected from the group consisting of a GM-CSF gene, a B7-1 gene, a B7-2 gene,  
3 an interleukin-2 gene, an interleukin-12 gene and an interferon gene.

1 12. The method of claim 4, wherein the adenovirus vector is defective  
2 in its E1 region.

1 13. The method of claim 4, wherein the adenovirus vector is defective  
2 in its E4 region.

1           14.    The method of claim 4, wherein the adenovirus vector is defective  
2    in its E3 region.

1           15.    The method of claim 4, wherein the vector has all viral genes  
2    deleted.

1           16.    The method of claim 3, wherein the vector comprises a DNA/virus  
2    complex.

1           17.    The method of claim 16, wherein the DNA is in plasmid form.

1           18.    The method of claim 3, wherein the vector comprises a DNA/  
2    liposome complex.

1           19.    The method of claim 3, wherein the vector comprises a  
2    recombinant adenovirus encoding an antigen or fragment thereof.

1           20.    The method of claim 1, wherein the immune response produces a  
2    protective effect against infectious pathogens or neoplasm.

1           21.    The method of claim 1, wherein said contacting step further  
2    comprises disposing the genetic vector containing the gene of interest on a

3 delivery device and applying the device having the genetic vector containing the  
4 gene of interest therein to the skin of the animal.

1 22. The method of claim 21, wherein the device includes a pad.

1 23. The method of claim 21, wherein the device includes an adhesive  
2 bandage-like device.

1 24. A method of non-invasively inducing an anti-tumor immune  
2 response in an animal in need of such treatment, comprising the step of:  
3 contacting skin of the animal topically by applying to the skin an  
4 immunologically effective concentration of a vector containing a transgene which  
5 encodes an antigen or fragment thereof which induces an anti-tumor effect in the  
6 animal following administration.

1 25. The method of claim 24, wherein the genetic vector comprises  
2 genetic vectors capable of expressing a transgene.

1 26. The method of claim 25, wherein the genetic vector is selected from  
2 the group consisting of viral vector and plasmid DNA.

1 27. The method of claim 25, wherein the genetic vector is an  
2 adenovirus.

1           28.     The method of claim 24, wherein the transgene encodes an antigen  
2     or fragment thereof.

1           29.     The method of claim 28, wherein the antigen or fragment thereof  
2     can be used to produce an immune response against a neoplasm.

1           30.     The method of claim 28, wherein the transgene encoding for the  
2     antigen includes oncogenes, tumor-suppressor genes, and tumor-associated genes.

1           31.     The method of claim 24, wherein the immunologically effective  
2     amount of the genetic vector is at least approximately 100 plaque forming units  
3     (pfu) for an adenovirus vector and at least 1 ng of DNA for plasmid.

1           32.     The method of claim 25, wherein the vector encodes an immune  
2     modulatory gene.

1           33.     The method of claim 32, wherein the vector further encodes a co-  
2     stimulatory gene and a cytokine gene.

1           34.     The method of claim 32, wherein the immune modulatory gene is  
2     selected from the group consisting of a GM-CSF gene, a B7-1 gene, a B7-2 gene,  
3     an interleukin-2 gene, an interleukin-12 gene and an interferon gene.

1           35.     The method of claim 27, wherein the adenovirus vector is defective  
2     in its E1 region.

1           36.     The method of claim 27, wherein the adenovirus vector is defective  
2     in its E4 region.

1           37.     The method of claim 27, wherein the adenovirus vector is defective  
2     in its E3 region.

1           38.     The method of claim 27, wherein the vector has all viral genes  
2     deleted.

1           39.     The method of claim 26, wherein the vector comprises a DNA/virus  
2     complex.

1           40.     The method of claim 39, wherein the DNA is in plasmid form.

1           41.     The method of claim 26, wherein the vector comprises a DNA/  
2     liposome complex.

1           42.     The method of claim 27, wherein the vector comprises a  
2     recombinant adenovirus encoding an antigen or fragment thereof.

1           43.     The method of claim 24, wherein the immune response produces  
2     an anti-tumor effect.

1           44.     The method of claim 24, wherein said contacting step further  
2     comprises disposing the genetic vector containing the gene of interest on a  
3     delivery device and applying the device having the genetic vector containing the  
4     gene of interest therein to the skin of the animal.

1           45.     The method of claim 44, wherein the device includes a pad.

1           46.     The method of claim 44, wherein the device includes an adhesive  
2     bandage-like device.

1           47.     A method for forming a DNA/virus complex, said method  
2     comprising the steps of:  
3           providing a suitable viral vector;  
4           providing a DNA sample to be complexed with the viral vector; and  
5           mixing together the viral vector and the DNA sample in the presence of  
6     poly-L-lysine.

1           48.     The method of claim 47, wherein viral vector is an adenovirus.



1           49.     The method of claim 47, wherein the DNA sample includes a gene  
2     of interest.

1           50.     The method of claim 49, wherein the gene encodes for an antigen  
2     or fragment thereof.

1           51.     The method of claim 47, wherein the ratio of the poly-L-lysine  
2     (PLL) to DNA sample ranges from between approximately  $0.9\mu\text{g PLL} : 1.0\mu\text{g}$   
3     DNA to approximately  $9.0\mu\text{g PLL} : 1\mu\text{g DNA}$ .

1           52.     The method of claim 47, wherein the ratio of the poly-L-lysine  
2     (PLL) to adenovirus vector ranges from between approximately  $6.0\mu\text{g PLL} : 10^8$   
3     pfu adenovirus to  $6.0\mu\text{g PLL} : 10^{10}$  pfu adenovirus.

1           53.     A device for the delivery of a genetic vector to the surface of the  
2     skin of an animal, said device comprising:

3                 a skin contacting means comprised of a first sheet of material  
4     having a first side and a second side, said first side adapted to contact the surface  
5     of the skin of the animal, and a second sheet of material having a first side  
6     disposed opposite to said first side of said first sheet;

7                 said first sheet and said second sheet are bonded together around  
8     external portions thereof to define a central enclosed space therebetween for  
9     containing a genetic vector therein; and

10                   said material comprising said first sheet being structurally weaker  
11   than said material comprising said second sheet whereby when the genetic vector  
12   is disposed in said space, and a force is applied to said first side of said second  
13   sheet, said first sheet breaks before said second sheet allowing the genetic vector  
14   to contact the skin of the animal.


1               54.    A device according to claim 53, wherein said first side of said first  
2   sheet includes an adhesive disposed about the periphery thereof to affix said  
3   device to the surface of the skin of the animal wherein the portion of said first  
4   sheet superimposed over said space is substantially free of adhesive.

1               55.    A device according to claim 53, wherein said sheets are comprised  
2   of a material impermeable to the genetic vector.

1               56.    A device according to claim 53, wherein said sheets are comprised  
2   of polymeric material.

1/12

FIG-1



2/12





FIG-2A

3/12



**FIG-2B**

4/12




FIG-3B





FIG-3A

5/12



6/12





FIG-5



7/12



**FIG-6**

8/12






FIG-7

9/12



DNA/Liposome


**FIG-8B**




DNA/Ad

**FIG-8A**


10/12



11/12



12/12



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/16739

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 48/00; C12N 5/10, 15/09, 15/63

US CL :514/44; 435/320.1, 172.3, 69.1; 424/ 450, 277.1, 570

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/44; 435/320.1, 172.3, 69.1; 424/ 450, 277.1, 570

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN, BIOSIS, MEDLINE, CAPLUS, CANCERLIT, EMBASE  
search terms: topical, vector, skin, plasmid

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	YOKOYAMA et al. DNA immunization: Effects of vehicle and route of administration on the induction of protective antiviral immunity. FEMS Immunology and Medical Microbiology. 1996, Vol. 14, No. 4, pages 221-230, see entire article.	1-56
X	LU et al. Topical application of viral vectors for epidermal gene transfer. Journal of Investigative Dermatology. May 1997, Vol. 108, No. 5, pages 803-808, see entire article.	1-6, 8-9, 16, 19-20
Y		7, 10, 11-15, 17-18, 21-56

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A" document defining the general state of the art which is not considered to be of particular relevance	*X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E" earlier document published on or after the international filing date	*Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&"	document member of the same patent family
*O" document referring to an oral disclosure, use, exhibition or other means		
*P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

22 OCTOBER 1998

Date of mailing of the international search report

10 NOV 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KAREN M. HAUDA

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/16739

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NIEMIEC et al. Perifollicular transgenic expression of human interleukin-1 receptor antagonist protein following topical application of novel liposome-plasmid DNA formulations in vivo. Journal of Pharmaceutical Sciences. June 1997, Vol. 86, No. 6, pages 701-708.	1, 2, 5, 6, 8, 9, 16
Y		3-4, 7, 10, 11-15, 17-56
Y, P	WEINER, N. Targeted follicular delivery of macromolecules via liposomes. International J. of Pharmaceutics. January 1998, Vol. 162, No. 1-2, pages 29-38, see especially pages 35-38.	1-56
Y, P	US 5,679,647 A (CARSON et al.) 21 October 1997, see entire patent.	1-56
Y, P	WO 98/03641 A1 (CRANDALL, W.T.) 29 January 1998, see entire patent.	1-56